Wells Fargo Maintains Equal-Weight on Applied Genetic Techs, Lowers Price Target to $0.4
Wells Fargo analyst Yanan Zhu maintains Applied Genetic Techs (NASDAQ:AGTC) with a Equal-Weight and lowers the price target from $0.5 to $0.4.
HC Wainwright & Co. Downgrades Applied Genetic Techs to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Neutral.
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday.
Wedbush Downgrades Applied Genetic Techs to Neutral
Wedbush analyst David Nierengarten downgrades Applied Genetic Techs (NASDAQ:AGTC) from Outperform to Neutral.
Stifel Downgrades Applied Genetic Techs to Hold, Lowers Price Target to $0.34
Stifel analyst Dae Gon Ha downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Hold and lowers the price target from $3 to $0.34.
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million.
Small Eye-Focused Gene Therapy Company Applied Genetic Goes Private In $24M Deal
The newly established portfolio company of Syncona Limited has agreed to acquire Applied Genetic Technologies Corp (NASDAQ:AGTC) for approximately $23.5 million ($0.34 per…
Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket
Gainers
Applied Genetic Technologies Corporation (NASDAQ: AGTC) rose 70.8% to $0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.
Syncona Announced Sunday it Will Acquire Applied Genetic Technologies Corporation for $0.34/Share in Cash Plus Up to $0.73 per CVR
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced t